Aurobindo Pharma has cleared one of the last major obstacles standing between it and a deeper foothold in the US generic drug market. The company's American subsidiary, Aurobindo Pharma USA, announced it received approval from the US Federal Trade Commission to proceed with its acquisition of Lannett Company LLC, a Pennsylvania-based generics manufacturer.

I've tracked enough cross-border pharma deals to know that FTC sign-off rarely comes free. This one came with a condition that tells you a lot about how regulators are watching the generic drug space right now.

The Deal Terms and What Changed

The transaction is valued at $250 million on a cash-free, debt-free basis, inclusive of normalized working capital. Aurobindo first agreed to acquire 100 percent of Lannett back in July 2025, and the companies now expect the deal to close before the end of June 2026.

But approval did not come without strings attached. The FTC required Aurobindo to divest four generic pharmaceutical products as a condition of closing. According to the regulator, the acquisition would have combined two of only a limited number of competitors making those specific drugs, a concentration the FTC said could threaten patients who rely on them for critical relief.

Key terms of the consent order:

  • Aurobindo must sell the four affected drugs to Quagen Pharmaceuticals, a New Jersey-based generics maker.
  • The divestiture is designed to preserve competition in those specific product markets.
  • The rest of the acquisition proceeds as planned once the divestiture is executed.

This is a familiar pattern in pharma consolidation. Regulators tend to approve the broader strategic logic of a deal while carving out the narrow slices where it would otherwise reduce competition to dangerous levels.

Why Lannett Was an Attractive Target

Lannett specializes in complex, non-opioid controlled substances, a niche corner of the generics market that requires specialized manufacturing capability and regulatory experience. The company's facility in Seymour, Indiana, can scale production to roughly 4 billion doses annually, giving Aurobindo a significant domestic manufacturing base.

That detail matters beyond the balance sheet. Adding US-based production capacity aligns with broader policy pressure on pharmaceutical companies to strengthen domestic supply chains rather than depend heavily on overseas manufacturing.

What This Means for Aurobindo's US Strategy

Swami S. Iyer, chief executive officer of Aurobindo Pharma USA, called the acquisition a compelling strategic and financial opportunity, one that accelerates revenue growth while strengthening the company's manufacturing footprint and expanding its position in non-opioid controlled substances.

The financial case looks straightforward on paper:

  • The deal is expected to be immediately accretive to Aurobindo Group's earnings per share.
  • Management anticipates meaningful cost efficiencies and SG&A synergies.
  • The combined portfolio expands Aurobindo's reach in complex generics.

Lannett CEO Tim Crew framed the deal from the other side, noting that Aurobindo's market reach and resources should help make the combined portfolio more affordable and accessible for patients.

For Aurobindo, this is part of a longer pattern. The company has been steadily building out its US presence through acquisitions, viewing inorganic growth as the faster route to scale in a market where organic expansion takes years of regulatory groundwork.

Risks Still on the Table

FTC approval removes the single biggest regulatory uncertainty, but it does not eliminate execution risk. Integration of operations, realization of projected synergies, and the actual EPS impact will all play out over the coming quarters rather than at signing.

Investors watching this deal should track:

  • Confirmation that the divestiture to Quagen closes cleanly and on schedule.
  • Whether projected cost synergies materialize as forecast.
  • Aurobindo's quarterly disclosures on integration progress once the deal closes.

The transaction is expected to close before the end of June 2026, subject to those remaining customary conditions.